tradingkey.logo
tradingkey.logo
Suchen

Aclarion Inc

ACON
Zur Watchlist hinzufügen
3.160USD
-0.060-1.86%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
7.73MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Aclarion Inc Unternehmen

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

Aclarion Inc Informationen

BörsenkürzelACON
Name des UnternehmensAclarion Inc
IPO-datumApr 22, 2022
CEONess (Brent)
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeApr 22
Addresse8181 Arista Place
StadtBROOMFIELD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl80021
Telefon18332752266
Websitehttps://aclarion.com/
BörsenkürzelACON
IPO-datumApr 22, 2022
CEONess (Brent)

Führungskräfte von Aclarion Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.30K
+99.79%
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
5.66K
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.30K
+99.79%
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
5.66K
--
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
SEG Opportunity Fund LLC
9.91%
Geode Capital Management, L.L.C.
1.25%
UBS Financial Services, Inc.
0.39%
CAPTRUST Financial Advisors
0.35%
The Vanguard Group, Inc.
0.30%
Andere
87.80%
Aktionäre
Aktionäre
Anteil
SEG Opportunity Fund LLC
9.91%
Geode Capital Management, L.L.C.
1.25%
UBS Financial Services, Inc.
0.39%
CAPTRUST Financial Advisors
0.35%
The Vanguard Group, Inc.
0.30%
Andere
87.80%
Aktionärstypen
Aktionäre
Anteil
Corporation
9.91%
Investment Advisor
1.31%
Investment Advisor/Hedge Fund
1.25%
Individual Investor
0.07%
Hedge Fund
0.03%
Andere
87.43%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
15
58.05K
2.32%
+16.68K
2025Q4
15
31.25K
1.59%
--
2025Q3
15
31.25K
0.88%
+26.14K
2025Q2
9
2.11K
0.08%
+1.65K
2025Q1
16
366.00
0.00%
+366.00
2024Q4
14
--
0.00%
--
2024Q3
14
--
0.00%
--
2024Q2
21
--
0.00%
--
2024Q1
22
--
0.00%
--
2023Q4
21
--
0.00%
--
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
SEG Opportunity Fund LLC
244.04K
10.69%
+244.04K
--
Mar 25, 2026
Geode Capital Management, L.L.C.
2.06K
0.07%
--
--
Jan 31, 2026
UBS Financial Services, Inc.
1.05K
0.04%
+1.05K
--
Dec 31, 2025
CAPTRUST Financial Advisors
10.00K
0.35%
--
--
Dec 31, 2025
The Vanguard Group, Inc.
6.78K
0.24%
--
--
Feb 28, 2026
Ness (Brent)
13.00
0%
+10.00
+333.33%
Nov 26, 2025
Neal (David K)
2.00
0%
+2.00
--
May 09, 2025
Wesemann (William G)
1.00
0%
+1.00
--
May 09, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 02, 2024
Merger
16→1
Jan 02, 2024
Merger
16→1
Mehr Anzeigen
KeyAI